首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

市場調查報告書

商品編碼

1936027

腫瘤學中的單株抗體：全球市場

Monoclonal Antibodies for Oncology: Global Markets

出版日期: 2026年02月06日 | 出版商:

BCC Research | 英文 229 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

全球腫瘤單株抗體市場預計將從 2025 年的 1,293 億美元成長到 2030 年底的 2,280 億美元，在預測期（2025-2030 年）內以 12% 的複合年成長率成長。

預計北美市場將從 2025 年的 745 億美元成長到 2030 年底的 1,322 億美元，在預測期（2025-2030 年）內以 12.2% 的複合年成長率成長。

歐洲市場預計將從 2025 年的 292 億美元成長到 2030 年底的 507 億美元，在預測期內實現 11.7% 的複合年成長率。

本報告檢視了腫瘤領域的全球單株抗體市場，並提供了市場概況、市場影響因素和市場機會分析、技術趨勢、法律制度、市場規模趨勢和預測、按各個細分市場和地區進行的詳細分析以及主要企業的概況。

市場動態
市場促進因素
癌症發生率加速上升
腫瘤學領域未滿足的醫療需求及單株抗體的作用
企業研發支出增加
政府增加撥款和醫藥品研究開發費用
市場限制
單株抗體高成本
獨特性喪失與一般化
腫瘤專科醫生短缺
市場機遇
單株抗體在腫瘤學中的潛力
新興市場

第4章：監理現狀

概述
美國
歐洲
亞太地區

第5章新興技術、臨床試驗分析與專利分析

概述
AI
免疫療法和細胞療法
新興生物標記
臨床試驗分析
按研究類型進行的臨床試驗分析
臨床試驗分析：按狀態
臨床試驗分析：按階段
重點總結
專利分析
重點總結

第6章市場區隔分析

細分市場分析
全球腫瘤單株抗體市場（按類型分類）
重點總結
人性化
人類
嵌合體
全球腫瘤單株抗體市場（按癌症類型分類）
重點總結
肺癌
乳癌
大腸直腸癌
淋巴瘤
白血病
黑色素瘤
多發性骨髓瘤
其他癌症
地理細分
全球腫瘤單株抗體市場（按地區分類）
重點總結
北美洲
歐洲
亞太地區
南美洲
中東和非洲

第7章競爭訊息

重點總結
競爭格局
企業市場占有率分析

第8章全球腫瘤單株抗體市場的永續性：ESG視角

ESG簡介
全球腫瘤單株抗體市場的永續性
ESG觀點
環境影響
對社會的影響
管治影響
ESG風險評估
結論

第9章附錄

調查方法
簡稱
來源
公司簡介
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC
JAZZ PHARMACEUTICALS INC.
JOHNSON & JOHNSON
LILLY USA LLC.
MERCK & CO. INC.
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
新興企業/市場顛覆者

簡介目錄圖表

Product Code: PHM261B

The global market for monoclonal antibodies in oncology is expected to grow from $129.3 billion in 2025 and is projected to reach $228 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12% during the forecast period of 2025 to 2030.

The North American market for monoclonal antibodies in oncology is expected to grow from $74.5 billion in 2025 and is projected to reach $132.2 billion by the end of 2030, at a CAGR of 12.2% during the forecast period of 2025 to 2030.

The European market for monoclonal antibodies in oncology is expected to grow from $29.2 billion in 2025 and is projected to reach $50.7 billion by the end of 2030, at a CAGR of 11.7% during the forecast period of 2025 to 2030.

Report Scope

The report provides detailed information on monoclonal antibodies in oncology. This report analyzes the market trends and includes global revenue ($ million) for the base year 2024, estimated data for 2025, and forecast data from 2025 through 2030. The report highlights the current and future market potential of monoclonal antibodies in oncology and provides a detailed analysis of the competitive environment. It includes regulatory scenarios, drivers, restraints and opportunities, as well as market projections for 2030 and the market share for key companies.

The market scope in this report is segmented by type, cancer type and region. By type, the market is segmented into humanized, human and chimeric. The cancer type segment is characterized into lung cancer, breast cancer, colorectal cancer, lymphoma, leukemia, melanoma, multiple myeloma and other cancers.

The region covered in this study includes North America, Europe, Asia-Pacific, the Middle East and Africa (MEA) and South America. The regional segment provides a detailed analysis of major countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia and India.

The report aims to:

Analyze types of monoclonal antibodies in oncology.
Analyze global market size and segmentation.
Understand market constraints and drivers.
Provide detailed market forecasts through 2030.
Assess market shares, competitiveness and industry structure.
Identify potential long-term impacts on the market for monoclonal antibodies in oncology.

Report Includes

91 data tables and 59 additional tables
In-depth analysis of the global markets for monoclonal antibodies (mAbs) for oncology
Analyses of the global market trends, with historic revenue (sales data) from 2022 to 2024, estimates for 2025 and projections of CAGRs through 2030
Estimates of the current market size and revenue prospects for the global market, along with a corresponding market share analysis based on type, cancer type and region
Facts and figures about market dynamics, opportunities and deterrents, technological advances, regulations, prospects and the impact of macroeconomic variables
Highlights of promising new advancements in monoclonal antibody-based nanoparticle therapy in cancer treatment, the emergence of next-generation therapeutic inhibitors, their potential and mechanism of action
Insights derived from Porter's Five Forces model, as well as global supply chain analyses
Review of the regulatory landscape featuring the U.S. premarket notifications and approvals with emphasis on recently approved products as well as products under development or in different stages of clinical trials
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
A relevant patent analysis, featuring key granted and published patents
Analysis of the industry structure, including companies' market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
Profiles of the leading companies, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Co., Johnson & Johnson Services, AstraZeneca, and Amgen Inc.

Chapter 1 Executive Summary

Market Outlook
Scope of Report
Market Summary
Market Dynamics and Growth Factors
Emerging Technologies
Segmental Analysis
Regional Analysis
Conclusion

Chapter 2 Market Overview

Overview
Macroeconomic Factors Analysis
Impact of U.S. Tariffs on the Pharmaceutical Industry
Healthcare Expenditure
Aging Population
Geopolitical Risks, Trade Wars and Supply Chain Disruptions
Impact of Global Economic Growth (GDP) on the Pharmaceutical Sector
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential for New Entrants
Threat of Substitutes
Competitiveness in the Industry

Chapter 3 Market Dynamics

Market Dynamics
Market Drivers
Acceleration in Cancer Rates
Unmet Treatment Need and the Role of Monoclonal Antibodies in Oncology
Increasing R&D Spending by Companies
Rise in Government Funding and Pharmaceutical R&D Spending
Market Restraints
High Cost of Monoclonal Antibodies
Loss of Exclusivity and Genericization
Shortage of Oncology Professionals
Market Opportunities
Potential of Monoclonal Antibodies in Oncology
Emerging Markets

Chapter 4 Regulatory Landscape

Overview
U.S.
Europe
Asia-Pacific

Chapter 5 Emerging Technologies, Clinical Trial Analysis and Patent Analysis

Overview
Artificial Intelligence (AI)
Immunotherapy and Cell Therapy
Emergent Biomarkers
Clinical Trial Analysis
Clinical Trials Analysis by Type of Study
Clinical Trials Analysis by Status
Clinical Trials Analysis by Phase
Key Takeaways
Patent Analysis
Key Takeaways

Chapter 6 Market Segmentation Analysis

Segmentation Breakdown
Global Market for Monoclonal Antibodies in Oncology, by Type
Key Takeaways
Humanized
Human
Chimeric
Global Market for Monoclonal Antibodies in Oncology, by Cancer Type
Key Takeaways
Lung Cancer
Breast Cancer
Colorectal Cancer
Lymphoma
Leukemia
Melanoma
Multiple Myeloma
Other Cancers
Geographic Breakdown
Global Market for Monoclonal Antibodies in Oncology, by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa

Chapter 7 Competitive Intelligence

Key Takeaways
Competitive Landscape
Company Share Analysis

Chapter 8 Sustainability in the Global Market for Monoclonal Antibodies in Oncology: An ESG Perspective

Introduction to ESG
Sustainability in the Global Market for Monoclonal Antibodies in Oncology
ESG Perspective
Environmental Impact
Social Impact
Governance Impact
ESG Risk Ratings
Conclusion

Chapter 9 Appendix

Methodology
Abbreviations
Sources
Company Profiles
ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
GSK PLC
JAZZ PHARMACEUTICALS INC.
JOHNSON & JOHNSON
LILLY USA LLC.
MERCK & CO. INC.
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Emerging Companies/Market Disruptors

簡介目錄圖表

List of Tables

Summary Table : Global Market for Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 1 : Current Health Expenditure, by Country, 2021-2023
Table 2 : National Cancer Institute Funding, by Mechanism, 2020-2024
Table 3 : Average Price of a Few Monoclonal Antibodies
Table 4 : Few Approved Biosimilars in the Market
Table 5 : Clinical Trials in Monoclonal Antibodies in Oncology, by Type of Study, as of September 2025
Table 6 : Clinical Trials in Monoclonal Antibodies in Oncology, by Status, as of September 2025
Table 7 : Clinical Trials in Monoclonal Antibodies in Oncology, by Phase, as of September 2025
Table 8 : List of Selected Monoclonal Antibodies Clinical Trials Studies
Table 9 : List of Selected Recent Patents Related to Monoclonal Antibodies, 2024 - 2025
Table 10 : Global Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 11 : Top Humanized mAbs in the Global Market for Monoclonal Antibodies in Oncology, 2023-2024
Table 12 : Global Market for Humanized Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 13 : Top Human mAbs in the Global Market for Monoclonal Antibodies in Oncology, 2023 - 2024
Table 14 : Global Market for Human Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 15 : Top Chimeric mAbs in the Global Market for Monoclonal Antibodies in Oncology, 2023 - 2024
Table 16 : Global Market for Chimeric Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 17 : Global Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 18 : Global Market for Lung Cancer in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 19 : Global Market for Breast Cancer in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 20 : Global Market for Colorectal Cancer in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 21 : Global Market for Lymphoma in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 22 : Global Market for Leukemia in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 23 : Global Market for Melanoma in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 24 : Global Market for Multiple Myeloma in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 25 : Global Market for Other Cancers in Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 26 : Global Market for Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 27 : North American Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 28 : North American Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 29 : North American Market for Monoclonal Antibodies in Oncology, by Country, Through 2030
Table 30 : U.S. Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 31 : U.S. Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 32 : Canadian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 33 : Canadian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 34 : Mexican Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 35 : Mexican Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 36 : European Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 37 : European Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 38 : European Market for Monoclonal Antibodies in Oncology, by Country, Through 2030
Table 39 : German Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 40 : German Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 41 : U.K. Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 42 : U.K. Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 43 : French Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 44 : French Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 45 : Italian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 46 : Italian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 47 : Spanish Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 48 : Spanish Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 49 : Rest of Europe Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 50 : Rest of Europe Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 51 : Cancer Cases in Asia-Pacific, by Sub-Region, 2022
Table 52 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 53 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 54 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Country, Through 2030
Table 55 : Chinese Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 56 : Chinese Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 57 : Japanese Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 58 : Japanese Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 59 : Indian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 60 : Indian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 61 : South Korean Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 62 : South Korean Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 63 : Australian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 64 : Australian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 65 : Rest of Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 66 : Rest of Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 67 : Cancer Cases in Selected South American Countries, 2022
Table 68 : South American Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 69 : South American Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 70 : South American Market for Monoclonal Antibodies in Oncology, by Country, Through 2030
Table 71 : Brazilian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 72 : Brazilian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 73 : Argentinian Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 74 : Argentinian Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 75 : Rest of South America Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 76 : Rest of South America Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 77 : MEA Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 78 : MEA Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 79 : MEA Market for Monoclonal Antibodies in Oncology, by Region, Through 2030
Table 80 : Middle East Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 81 : Middle East Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 82 : Approved mAbs in African Countries
Table 83 : African Market for Monoclonal Antibodies in Oncology, by Type, Through 2030
Table 84 : African Market for Monoclonal Antibodies in Oncology, by Cancer Type, Through 2030
Table 85 : Key Strategic Initiatives in Global Market for Monoclonal Antibodies in Oncology, 2024 - 2025
Table 86 : Key Focus Areas in ESG Metrics
Table 87 : ESG Rankings for Leading Companies in Monoclonal Antibodies in Oncology, 2025*
Table 88 : Abbreviations Used in this Report
Table 89 : Report Sources
Table 90 : AbbVie Inc.: Company Snapshot
Table 91 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
Table 92 : AbbVie Inc.: Product Portfolio
Table 93 : AbbVie Inc.: News/Key Developments, 2023-2025
Table 94 : Amgen Inc.: Company Snapshot
Table 95 : Amgen Inc.: Financial Performance, FY 2023 and 2024
Table 96 : Amgen Inc.: Product Portfolio
Table 97 : Amgen Inc.: News/Key Developments, 2022-2025
Table 98 : AstraZeneca: Company Snapshot
Table 99 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 100 : AstraZeneca: Product Portfolio
Table 101 : AstraZeneca: News/Recent Developments, 2023-2025
Table 102 : Bristol-Myers Squibb Co.: Company Snapshot
Table 103 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
Table 104 : Bristol-Myers Squibb Co.: Product Portfolio
Table 105 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2025
Table 106 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 107 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
Table 108 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 109 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2022-2025
Table 110 : Gilead Sciences Inc.: Company Snapshot
Table 111 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
Table 112 : Gilead Sciences Inc.: Product Portfolio
Table 113 : Gilead Sciences Inc.: News/Key Developments, 2023-2024
Table 114 : GSK plc: Company Snapshot
Table 115 : GSK plc: Financial Performance, FY 2023 and 2024
Table 116 : GSK plc: Product Portfolio
Table 117 : GSK plc: News/Key Developments, 2023-2025
Table 118 : Jazz Pharmaceuticals Inc.: Company Snapshot
Table 119 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 120 : Jazz Pharmaceuticals Inc.: Product Portfolio
Table 121 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2024-2025
Table 122 : Johnson & Johnson: Company Snapshot
Table 123 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
Table 124 : Johnson & Johnson: Product Portfolio
Table 125 : Johnson & Johnson.: News/Key Developments, 2022-2025
Table 126 : Lilly USA LLC.: Company Snapshot
Table 127 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
Table 128 : Lilly USA LLC.: Product Portfolio
Table 129 : Lilly USA LLC.: News/Key Development, 2022-2023
Table 130 : Merck & Co. Inc.: Company Snapshot
Table 131 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 132 : Merck & Co. Inc.: Product Portfolio
Table 133 : Merck & Co. Inc.: News/Key Developments, 2022-2025
Table 134 : Pfizer Inc.: Company Snapshot
Table 135 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 136 : Pfizer Inc.: Product Portfolio
Table 137 : Pfizer Inc.: News/Key Developments, 2023-2025
Table 138 : Regeneron Pharmaceuticals Inc.: Company Snapshot
Table 139 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
Table 140 : Regeneron Pharmaceuticals Inc.: Product Portfolio
Table 141 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2025
Table 142 : Sanofi: Company Snapshot
Table 143 : Sanofi: Financial Performance, FY 2023 and 2024
Table 144 : Sanofi: Product Portfolio
Table 145 : Sanofi: News/Key Developments, 2022-2025
Table 146 : Teva Pharmaceutical Industries Ltd.: Company Snapshot
Table 147 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2023 and 2024
Table 148 : Teva Pharmaceutical Industries Ltd.: Product Portfolio
Table 149 : A Few Emerging Companies in the Global Market for Monoclonal Antibodies in Oncology

List of Figures

Summary Figure : Global Market Shares for Monoclonal Antibodies in Oncology, by Region, 2024
Figure 1 : Porter's Five Forces Analysis of the Global Market for Monoclonal Antibodies in Oncology
Figure 2 : Market Dynamics of Monoclonal Antibodies in Oncology
Figure 3 : Distribution Share of the Most Frequent Cancer Types in Women*, 2022
Figure 4 : Distribution Share of the Most Frequent Cancer Types in Men*, 2022
Figure 5 : Estimated New Cancer Cases and Deaths in the U.S., 2024
Figure 6 : Share of Companies' R&D Expenditure, by Function, 2022
Figure 7 : Global Pharmaceutical R&D Spending and Growth, 2020-2026
Figure 8 : Global Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 9 : Global Market Shares for Humanized Monoclonal Antibodies in Oncology, by Region, 2024
Figure 10 : Global Market Shares for Human Monoclonal Antibodies in Oncology, by Region, 2024
Figure 11 : Global Market Shares for Chimeric Monoclonal Antibodies in Oncology, by Region, 2024
Figure 12 : Global Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 13 : Global Market Shares for Lung Cancer in Monoclonal Antibodies in Oncology, by Region, 2024
Figure 14 : Global Market Shares for Breast Cancer in Monoclonal Antibodies in Oncology, by Region, 2024
Figure 15 : Global Market Shares for Colorectal Cancer in Monoclonal Antibodies in Oncology, by Region, 2024
Figure 16 : Global Market Shares for Lymphoma in Monoclonal Antibodies in Oncology, by Region, 2024
Figure 17 : Global Market Shares for Leukemia in Monoclonal Antibodies in Oncology, by Region, 2024
Figure 18 : Global Market Shares for Melanoma in Monoclonal Antibodies in Oncology, by Region, 2024
Figure 19 : Global Market Shares for Multiple Myeloma in Monoclonal Antibodies in Oncology, by Region, 2024
Figure 20 : Global Market Shares for Other Cancers in Monoclonal Antibodies in Oncology, by Region, 2024
Figure 21 : Global Market Shares for Monoclonal Antibodies in Oncology, by Region, 2024
Figure 22 : North American Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 23 : North American Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 24 : North American Market Shares for Monoclonal Antibodies in Oncology, by Country, 2024
Figure 25 : U.S. Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 26 : U.S. Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 27 : Canadian Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 28 : Canadian Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 29 : Mexican Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 30 : Mexican Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 31 : European Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 32 : European Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 33 : European Market Shares for Monoclonal Antibodies in Oncology, by Country, 2024
Figure 34 : German Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 35 : German Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 36 : U.K. Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 37 : U.K. Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 38 : French Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 39 : French Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 40 : Italian Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 41 : Italian Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 42 : Spanish Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 43 : Spanish Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 44 : Rest of Europe Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 45 : Rest of Europe Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 46 : Asia-Pacific Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 47 : Asia-Pacific Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 48 : Asia-Pacific Market Shares for Monoclonal Antibodies in Oncology, by Country, 2024
Figure 49 : Chinese Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 50 : Chinese Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 51 : Japanese Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 52 : Japanese Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 53 : Indian Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 54 : Indian Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 55 : South Korean Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 56 : South Korean Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 57 : Australian Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 58 : Australian Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 59 : Rest of Asia-Pacific Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 60 : Rest of Asia-Pacific Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 61 : South American Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 62 : South American Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 63 : South American Market Shares for Monoclonal Antibodies in Oncology, by Country, 2024
Figure 64 : Brazilian Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 65 : Brazilian Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 66 : Argentinian Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 67 : Argentinian Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 68 : Rest of South America Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 69 : Rest of South America Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 70 : MEA Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 71 : MEA Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 72 : MEA Market Shares for Monoclonal Antibodies in Oncology, by Region, 2024
Figure 73 : Middle East Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 74 : Middle East Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 75 : African Market Shares for Monoclonal Antibodies in Oncology, by Type, 2024
Figure 76 : African Market Shares for Monoclonal Antibodies in Oncology, by Cancer Type, 2024
Figure 77 : Top 10 Blockbuster Monoclonal Antibodies in Oncology, by Sales Revenue, 2023-2024
Figure 78 : Global Market Shares for Monoclonal Antibodies in Oncology, by Company, 2024
Figure 79 : Pillars of ESG
Figure 80 : Advantages of ESG for Companies
Figure 81 : AbbVie Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 82 : AbbVie Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 83 : Amgen Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 84 : Amgen Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 85 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
Figure 86 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
Figure 87 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2024
Figure 88 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2024
Figure 89 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2024
Figure 90 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2024
Figure 91 : Gilead Sciences Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 92 : Gilead Sciences Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 93 : GSK plc: Revenue Shares, by Business Unit, FY 2024
Figure 94 : GSK plc: Revenue Shares, by Country/Region, FY 2024
Figure 95 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 96 : Jazz Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 97 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2024
Figure 98 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2024
Figure 99 : Lilly USA LLC.: Revenue Shares, by Business Unit, FY 2024
Figure 100 : Lilly USA LLC.: Revenue Shares, by Country/Region, FY 2024
Figure 101 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 102 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 103 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 104 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 105 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 106 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
Figure 107 : Sanofi: Revenue Shares, by Country/Region, FY 2024
Figure 108 : Teva Pharmaceutical Industries Ltd.: Revenue Shares, by Country/Region, FY 2024